TORONTO, ONTARIO – (October 22, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) today granted its independent directors and a new addition to its management team options to purchase a total of 250,000 common shares of Antibe pursuant to the Corporation’s stock option plan. Each option bares an exercise price of $0.55, being the closing price of Antibe shares on October 21, 2013, and an expiry date of October 21, 2023. Twenty-five percent of the options vest on the grant date and 1/36th of the remaining options vest in each of the subsequent 36 months.

The Corporation is also pleased to announce that Jeremy Grushcow, Ph.D., J.D. has been appointed to the part-time role of VP Legal and Strategy. Dr. Grushcow has over ten years of experience in law, working with and representing public and private companies. He also has experience with venture capital and private equity firms in the acquisition, financing, development, operation and sale of pharmaceutical and life sciences companies in the U.S. and Canada. He is endorsed by PLC for his corporate and commercial expertise in Life Sciences, and is recognized for his transactional expertise in the 2013 edition of The International Who’s Who of Life Sciences Lawyers. Dr. Grushcow holds a B.Sc. from the University of Toronto, a Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago, and a J.D. with honors from the University of Chicago Law School, where he was awarded the John M. Olin Prize given to the outstanding student in Law and Economics. He has been admitted to the Bar in Ontario, New York and Illinois.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information

Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095

Read all news


This is an external link. Click “OK” to continue.